PTAB Invalidates Humira Patent In Coherus Challenge

Law360, New York (May 17, 2017, 5:11 PM EDT) -- The Patent Trial and Appeal Board invalidated a key patent for AbbVie Biotechnology Ltd.’s mega-blockbuster autoimmune disease drug Humira on Tuesday, finding the patent would have been obvious at the time of the invention.

The PTAB’s decision in inter partes review is a victory for Coherus BioSciences Inc., a California biosimilars company that, according to published reports, has been looking to launch a copycat of Humira, the world’s best-selling pharmaceutical.

The patent covers a Humira dosing regimen to treat rheumatoid arthritis. Coherus argued it would have...
To view the full article, register now.